Daily Stock Analysis, CATB, Catabasis Pharmaceuticals Inc, priceseries

Catabasis Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
7.79
Close
7.70
High
7.79
Low
7.60
Previous Close
7.46
Daily Price Gain
0.24
YTD High
9.76
YTD High Date
Apr 11, 2019
YTD Low
4.02
YTD Low Date
Feb 15, 2019
YTD Price Change
3.27
YTD Gain
73.81%
52 Week High
9.76
52 Week High Date
Apr 11, 2019
52 Week Low
3.60
52 Week Low Date
Dec 27, 2018
52 Week Price Change
-0.80
52 Week Gain
-9.41%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 9. 2017
13.30
Mar 17. 2017
15.60
6 Trading Days
17.31%
Link
LONG
Sep 11. 2017
14.50
Sep 26. 2017
15.89
11 Trading Days
9.58%
Link
LONG
Sep 27. 2017
18.30
Oct 10. 2017
23.06
9 Trading Days
25.99%
Link
LONG
Feb 28. 2018
17.20
Mar 14. 2018
19.56
10 Trading Days
13.74%
Link
LONG
Jan 3. 2019
4.60
Jan 23. 2019
5.93
13 Trading Days
28.97%
Link
LONG
Mar 7. 2019
5.02
Apr 15. 2019
8.32
27 Trading Days
65.78%
Link
LONG
Jun 18. 2019
6.45
Jul 3. 2019
7.50
11 Trading Days
16.32%
Link
Company Information
Stock Symbol
CATB
Exchange
NasdaqGM
Company URL
http://www.catabasis.com
Company Phone
617-349-1971
CEO
Jill C. Milne
Headquarters
Massachusetts
Business Address
ONE KENDALL SQUARE, BLDG. 1400E, SUITE B14202, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001454789
About

Catabasis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of therapeutics for the treatment of cardiovascular, metabolic and inflammatory diseases. The company was founded by Jill C. Milne, Michael Jirousek and Steven Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.

Description

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy (DMD); CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia in patients for whom existing treatments are insufficient; and CAT-2003 that has completed Phase IIa trials for the treatment of patients with elevated triglycerides or hypertriglyceridemia. It is also developing CAT-4001 that is in preclinical stage for the treatment for severe, rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis. The company has collaboration agreements with dystrophy association for the development of CAT-1004, a treatment for DMD; and Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. Catabasis Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.